ClinicalTrials.gg
RecruitingNCT06878261JOURNEYUpdated Oct 9, 2026

A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)

A Phase 3 interventional study of Tezepelumab and Placebo in Chronic Obstructive Pulmonary Disease (COPD), sponsored by AstraZeneca. Recruiting at 284 sites in 22 countries. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 7 months later.
Updated Oct 9, 2026Site recruiting status changed8 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
990
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca — 14 open to participants now, 15 under way, 4 of them phase 3. Pulmonary Disease, Chronic Obstructive · AstraZeneca.

Planned enrollment
34th of 194
990 · median 137
Started
2025
with 12 others
Phase 3
76 of 284
4 open now
Primary completion
2029-03
later than 13 of 14 live
Registered
270th of 284
by date

Among the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, this one is the 34th largest by planned enrollment of the 194 interventional ones that give a count, is one of 13 that started in 2025, is one of 76 in phase 3, reaches primary completion later than 13 of the 14 other live ones, and was the 270th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

14 of the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 14 open studies →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, or all of them as a file.
02

Study summary

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

Read the detailed description

This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of tezepelumab in adults with moderate to very severe chronic obstructive pulmonary disease (COPD) receiving inhaled maintenance therapy and having had at least 2 moderate, or 1 severe, COPD exacerbations in the 12 months prior to Visit 1. Subjects will receive monthly subcutaneous injection of one of two different doses of tezepelumab, or placebo, with a maximum treatment duration of 76 weeks and a minimum of 52 weeks. The study also includes a off-treatment safety follow-up period of 12 weeks.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease (COPD)

Keywords

  • COPD
  • Moderate COPD
  • Severe COPD
  • Very Severe COPD
  • chronic obstructive pulmonary disease
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. ≥40 to ≤80 years old
  2. diagnosis ≥1 year,
  3. Post-BD ≥ 20% and ≤ 70% PN, FEV1/FVC \<0.70 at screening
  4. Triple (ICS+LABA+LAMA) or dual inhaled COPD therapy, if triple therapy is considered not appropriate, ≥3 consecutive months prior to V1
  5. ≥2 moderate or ≥1 severe COPD exacerbations in the prior year; At least 1 of 2 moderate exacerbations must require the use of systemic . At least one of the previous exacerbations should be confirmed to have occurred while the participant was on triple or dual inhaled maintenance therapy
  6. EOS ≥ 150 cells/μL during screening
  7. CAT ≥15 at screening
  8. Former or current smokers ≥10 pack-years

Exclusion criteria

Exclusion Criteria:

  1. Clin. important pulmonary disease or radiological findings suggestive of a respiratory disease other than
  2. Asthma, incl. pediatric, or ACOS
  3. Any unstable disorder that can impact participants safety or study outcomes
  4. Tuberculosis requiring treatment within 12 months prior V2
  5. current or past

    Concomitant therapies:

    • Macrolides (less than 6 months)
    • Systemic immuno-suppressive, -modulating medications
  6. LTOT >4.0 L/min or O2 saturation \<89% despite LTOT
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
990 participants (estimated)

Study arms

  • Experimental
    Dose 1 of Tezepelumab

    Tezepelumab, SC, Q4W

    Biological: Tezepelumab

  • Experimental
    Dose 2 of Tezepelumab

    Tezepelumab, SC, Q4W

    Biological: Tezepelumab

  • Placebo comparator
    Matching Placebo

    Matching placebo, SC, Q4W

    Other: Placebo

Interventions

  • BiologicalTezepelumab

    Tezepelumab subcutaneous injection

  • OtherPlacebo

    Placebo subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Annualised rate of moderate or severe COPD exacerbations

    The annualised moderate or severe COPD exacerbation rate (based on exacerbations reported by the investigator) up to 76 weeks treatment period compared to placebo.

    Time frame: Baseline up to 76 weeks

Secondary outcomes

  1. Change from baseline in post-BD FEV1

    Change from baseline in post-BD FEV1 at Week 52 compared to placebo. FEV1 is defined as the volume of air exhaled from the lungs in the first second of a forced expiration

    Time frame: From baseline to Week 52

  2. Change from baseline in pre-dose/pre-bronchodilator (pre-BD) forced expiratory volume in 1 second (FEV1)

    Change from baseline in pre-BD FEV1 at Week 52 compared to placebo. FEV1 is defined as the volume of air exhaled from the lungs in the first second of a forced expiration

    Time frame: From baseline to Week 52

  3. Change from baseline in the St. George's Respiratory Questionnaire (SGRQ) total score

    Change from baseline in the SGRQ total score over 52 weeks compared to placebo. SGRQ is a disease-specific instrument designed to measure impact on overall health, daily life, and perceived well-being in patients with obstructive airways disease. Scores range from 0 to 100, with lower scores indicating better health status.

    Time frame: From baseline over 52 weeks

  4. Annualised rate of moderate or severe COPD exacerbations among participants with EOS ≥ 300 cells/µL collected during screening visit.

    The annualised moderate or severe COPD exacerbation rate (based on exacerbations reported by the investigator) up to 76 weeks treatment period compared to placebo among participants with EOS ≥ 300 cells/µL collected during screening visit.

    Time frame: Baseline up to 76 weeks

  5. Annualised rate of severe COPD exacerbations

    The annualised severe COPD exacerbation rate (based on exacerbations reported by the investigator) up to 76 weeks treatment period compared to placebo

    Time frame: Baseline up to 76 weeks

  6. Annualised rate of COPD exacerbations requiring ER visit and/or hospitalisation

    The annualised rate of COPD exacerbation requiring ER visit and/or hospitalisation up to 76 weeks treatment period compared to placebo.

    Time frame: Baseline up to 76 Weeks

  7. Clinical meaningful improvement in St. George's Respiratory Questionnaire (SGRQ) total score

    Participants achieving a clinically meaningful improvement from baseline in SGRQ total score (4-point score decrease) over 52 weeks. SGRQ is a disease-specific instrument designed to measure impact on overall health, daily life, and perceived well-being in patients with obstructive airways disease. Scores range from 0 to 100, with lower scores indicating better health status.

    Time frame: From baseline over 52 weeks

  8. Change from baseline in the COPD assessment Test (CAT) total score

    Change from baseline in the CAT total score over 52 weeks CAT is an 8-item PRO that measures the impact of COPD on the health status of patients with COPD. The CAT has a scoring range of 0-40 with higher scores indicative of greater COPD impact on health status.

    Time frame: From baseline over 52 weeks

  9. Clinical meaningful improvement in COPD Assessment Test (CAT) total score

    Participants achieving a clinically meaningful improvement from baseline in CAT total score (2-point score decrease) over 52 weeks. CAT is an 8-item PRO that measures the impact of COPD on the health status of patients with COPD. The CAT has a scoring range of 0-40 with higher scores indicative of greater COPD impact on health status.

    Time frame: From baseline over 52 weeks

  10. Time to first moderate or severe COPD exacerbation

    Time to first occurrence of moderate or severe COPD exacerbation up to 76 weeks

    Time frame: Baseline up to 76 weeks

  11. Time to first severe COPD exacerbation

    Time to first occurrence of severe COPD exacerbation up to 76 weeks

    Time frame: Baseline up to 76 weeks

  12. Pharmacokinetics (PK): Serum trough concentrations

    Serum trough concentrations

    Time frame: Baseline, Week 24, Week 36, Week 52

  13. Immunogenicity of anti-drug antibodies (ADA)

    Incidence of anti-drug antibodies

    Time frame: Baseline, Week 24, Week 36, Week 52

07

Study locations

233 of 284 sites recruiting
  • Research Site
    Birmingham, Alabama 35205, United States
    Not yet recruiting
  • Research Site
    Cullman, Alabama 35055, United States
    Recruiting
  • Research Site
    Phoenix, Arizona 85044, United States
    Recruiting
  • Research Site
    Scottsdale, Arizona 85258, United States
    Recruiting
  • Research Site
    Inglewood, California 90301, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Los Angeles, California 90048, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Research Site
    Palo Alto, California 94304, United States
    Recruiting
  • Research Site
    Redding, California 96001, United States
    Recruiting
  • Research Site
    San Diego, California 92108, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Research Site
    New Britain, Connecticut 06051, United States
    Recruiting
  • Research Site
    Wilmington, Delaware 19803, United States
    Recruiting
  • Research Site
    Bay Pines, Florida 33744, United States
    Recruiting
  • Research Site
    Boynton Beach, Florida 33435, United States
    Recruiting
  • Research Site
    Clearwater, Florida 33765, United States
    Completed

    Not enrolling at this site — choose another above.

  • Research Site
    Fleming Island, Florida 32003, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Research Site
    Jacksonville, Florida 32209, United States
    Recruiting
  • Research Site
    Leesburg, Florida 34748, United States
    Recruiting
  • Research Site
    Margate, Florida 33063, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Miami, Florida 33126, United States
    Recruiting
  • Research Site
    Miami, Florida 33155, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Research Site
    Miami Lakes, Florida 33014, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Research Site
    Ocala, Florida 34470, United States
    Recruiting
  • Research Site
    Palmetto Bay, Florida 33157, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Research Site
    Winter Park, Florida 32789, United States
    Recruiting
  • Research Site
    Adairsville, Georgia 30103, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Research Site
    Atlanta, Georgia 30349, United States
    Recruiting
  • Research Site
    Cordele, Georgia 31015, United States
    Recruiting
  • Research Site
    Decatur, Georgia 30033, United States
    Recruiting
  • Research Site
    Fort Eisenhower, Georgia 30905, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Savannah, Georgia 31406, United States
    Recruiting
  • Research Site
    Evanston, Illinois 60201, United States
    Recruiting
  • Research Site
    Hinsdale, Illinois 60521, United States
    Not yet recruiting
  • Research Site
    Springfield, Illinois 62703, United States
    Not yet recruiting
  • Research Site
    Evansville, Indiana 47725, United States
    Recruiting
  • Research Site
    Indianapolis, Indiana 46202, United States
    Recruiting
  • Research Site
    Indianapolis, Indiana 46268, United States
    Recruiting
  • Research Site
    Kansas City, Kansas 66160, United States
    Recruiting
  • Research Site
    Bowling Green, Kentucky 42101, United States
    Recruiting
  • Research Site
    Owensboro, Kentucky 42301, United States
    Recruiting
  • Research Site
    Baltimore, Maryland 21224, United States
    Recruiting
  • Research Site
    Potomac, Maryland 20854, United States
    Recruiting
  • Research Site
    Rosedale, Maryland 21237, United States
    Recruiting
  • Research Site
    Ann Arbor, Michigan 48109, United States
    Recruiting
  • Research Site
    Minneapolis, Minnesota 55425, United States
    Recruiting
  • Research Site
    Hannibal, Missouri 63401, United States
    Recruiting
  • Research Site
    Staten Island, New York 10309, United States
    Recruiting
  • Research Site
    Syracuse, New York 13203, United States
    Recruiting
  • Research Site
    The Bronx, New York 10459, United States
    Recruiting
  • Research Site
    Charlotte, North Carolina 28277, United States
    Recruiting
  • Research Site
    Concord, North Carolina 28025, United States
    Not yet recruiting
  • Research Site
    Fayetteville, North Carolina 28303, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Oklahoma City, Oklahoma 73102, United States
    Recruiting
  • Research Site
    Tulsa, Oklahoma 74133, United States
    Recruiting
  • Research Site
    Grants Pass, Oregon 97527, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Horsham, Pennsylvania 19044, United States
    Not yet recruiting
  • Research Site
    Pittsburgh, Pennsylvania 15241, United States
    Not yet recruiting
  • Research Site
    Sayre, Pennsylvania 18840, United States
    Recruiting
  • Research Site
    Anderson, South Carolina 29621, United States
    Recruiting
  • Research Site
    Columbia, South Carolina 29204, United States
    Recruiting
  • Research Site
    Gaffney, South Carolina 29340, United States
    Recruiting
  • Research Site
    Little River, South Carolina 29566, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Research Site
    Spartanburg, South Carolina 29303, United States
    Recruiting
  • Research Site
    Union, South Carolina 29379, United States
    Recruiting
  • Research Site
    Rapid City, South Dakota 57702, United States
    Recruiting
  • Research Site
    Hendersonville, Tennessee 37075, United States
    Not yet recruiting
  • Research Site
    Knoxville, Tennessee 37919, United States
    Recruiting
  • Research Site
    Lebanon, Tennessee 37087, United States
    Not yet recruiting
  • Research Site
    Boerne, Texas 78006, United States
    Recruiting
  • Research Site
    El Paso, Texas 79902, United States
    Recruiting
  • Research Site
    Houston, Texas 77008, United States
    Recruiting
  • Research Site
    Houston, Texas 77074, United States
    Recruiting
  • Research Site
    Houston, Texas 77094, United States
    Recruiting
  • Research Site
    Lewisville, Texas 75067, United States
    Recruiting
  • Research Site
    McKinney, Texas 75069, United States
    Recruiting
  • Research Site
    Mesquite, Texas 75149, United States
    Recruiting
  • Research Site
    San Antonio, Texas 78258, United States
    Recruiting
  • Research Site
    Colchester, Vermont 05446, United States
    Recruiting
  • Research Site
    Williamsburg, Virginia 23188, United States
    Recruiting
  • Research Site
    Everett, Washington 98208, United States
    Recruiting
  • Research Site
    Kenosha, Wisconsin 53142, United States
    Not yet recruiting
  • Research Site
    Alberdi, X5033DCE, Argentina
    Recruiting
  • Research Site
    Buenos Aires, C1425BEN, Argentina
    Recruiting
  • Research Site
    Ciudad de Buenos Aires, C1414AIF, Argentina
    Recruiting
  • Research Site
    Florida, B1602DQD, Argentina
    Recruiting
  • Research Site
    La Plata, B1900, Argentina
    Recruiting
  • Research Site
    La Plata, B1904, Argentina
    Recruiting
  • Research Site
    Mar del Plata, 7600, Argentina
    Recruiting
  • Research Site
    Mendoza, M5500CCG, Argentina
    Recruiting
  • Research Site
    Quilmes, B1878FNR, Argentina
    Recruiting
  • Research Site
    Rosario, 2000, Argentina
    Recruiting
  • Research Site
    San Fernando, B1646EBJ, Argentina
    Recruiting
  • Research Site
    San Juan Bautista, 1888, Argentina
    Recruiting
  • Research Site
    Coffs Harbour, 02450, Australia
    Recruiting
  • Research Site
    Frankston, 3199, Australia
    Recruiting
  • Research Site
    Garran, 2605, Australia
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Nedlands, 6009, Australia
    Recruiting
  • Research Site
    New Lambton, 2310, Australia
    Completed

    Not enrolling at this site — choose another above.

  • Research Site
    Spearwood, 6163, Australia
    Recruiting
  • Research Site
    Wollongong, 2500, Australia
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Woodville South, 5011, Australia
    Completed

    Not enrolling at this site — choose another above.

Showing the first 100 of 284 sites across 22 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Mar 2029, 47 months after the start.

Of 108 industry-sponsored phase 3 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 36. This study's planned 47 months is above that.

Counting every sponsor, half of 141 studies reached it within 23 months; a quarter within 14 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2025
First posted
Mar 14, 2025
StartActual
Mar 25, 2025
Primary completionEst.
Mar 13, 2029
CompletionEst.
Jun 5, 2029
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
8 sites added. 8 sites changed recruiting status (4 now suspended, 3 now recruiting, …)
Show 8 sites
  • Research Site · Los Angeles, United StatesRecruiting→Suspended
  • Research Site · Redding, United StatesSuspended→Recruiting
  • Research Site · Palmetto Bay, United StatesRecruiting→Suspended
  • Research Site · The Bronx, United StatesNot yet recruiting→Recruiting
  • Research Site · Bucharest, RomaniaNot yet recruiting→Recruiting
  • Research Site · Cluj-Napoca, RomaniaRecruiting→Suspended
  • Research Site · Timișoara, RomaniaRecruiting→Suspended
  • Research Site · Durban, South AfricaRecruiting→Not yet recruiting
Show 8 added (6 United States, 1 Peru, 1 South Africa)
  • Research Site · Birmingham, United States
  • Research Site · Hinsdale, United States
  • Research Site · Little River, United States
  • Research Site · Hendersonville, United States
  • Research Site · Lebanon, United States
  • Research Site · Kenosha, United States
  • Research Site · Lima, Peru
  • Research Site · Durban, South Africa
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    8 sites added. 11 sites changed recruiting status (5 now suspended, 4 now recruiting, …)
    Show 11 sites
    • Research Site · Los Angeles, United StatesRecruiting→Suspended
    • Research Site · Redding, United StatesSuspended→Recruiting
    • Research Site · Palmetto Bay, United StatesRecruiting→Suspended
    • Research Site · The Bronx, United StatesNot yet recruiting→Recruiting
    • Research Site · Lima, PeruRecruiting→Not yet recruiting
    • Research Site · Lima, PeruRecruiting→Suspended
    • Research Site · Lima, PeruWithdrawn→Recruiting
    • Research Site · Bucharest, RomaniaNot yet recruiting→Recruiting
    • Research Site · Cluj-Napoca, RomaniaRecruiting→Suspended
    • Research Site · Timișoara, RomaniaRecruiting→Suspended
    • Research Site · Durban, South AfricaRecruiting→Not yet recruiting
    Show 8 added (6 United States, 1 Peru, 1 South Africa)
    • Research Site · Birmingham, United States
    • Research Site · Hinsdale, United States
    • Research Site · Little River, United States
    • Research Site · Hendersonville, United States
    • Research Site · Lebanon, United States
    • Research Site · Kenosha, United States
    • Research Site · Lima, Peru
    • Research Site · Durban, South Africa
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06878261
Lead sponsor
AstraZeneca
Collaborators
Amgen
Responsible party
Sponsor
First posted
Mar 14, 2025
Start date
Mar 25, 2025
Primary completion
Mar 13, 2029 (estimated)
Completion
Jun 5, 2029 (estimated)
Last update
Oct 9, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479
MeiLan Han, MD
principal investigator · University of Michigan Health, Pulmonary & Critical Care Medicine,

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tezepelumab

Start the discussion